Ipsen and Rhythm enter into license agreement for Ipsen's peptide therapeutics

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
GE Opens First New Manufacturing Operation in Louisville, Ky...
Get set for Bupa Great Birmingham Run...
New Regional Aircraft Contracts and Support...
Harris Corporation's John Shipley Honored by U.S...
Farmers can use red diesel to help out during extreme weather...
Hogan Lovells' It's Not Just Peanuts Campaign Wins Legal Business...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Ipsen and Rhythm enter into license agreement for Ipsen's peptide therapeutics
Global biotechnology specialty care group Ipsen (Paris:IPN) (Euronext: IPN) and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, have concluded a license agreement for Ipsen's proprietary peptide therapeutics targeting obesity,...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search